On Friday, Shares of United Parcel Service, Inc. (NYSE:UPS), gained 1.32% to $98.79.
The following is an article written by Rimas Kapeskas of UPS
Imagine a factory or warehouse where employees can work freely, no longer constrained by computer workstations or scanners that can act as chokepoints on a shop floor. With the aid of multiple, hands-free devices, workers would simply follow real-time updates and instructions that appear in their line of sight, allowing them to work smarter and faster.
In addition to digital eyewear, picture wearables and fixed sensors communicating with each other and enterprise systems, assisting employees know exactly where they need to be and what to do next - at precisely the right time. Employees and wearables work in unison, reducing error rates and keeping everyone safer and more productive.
United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. It operates in three segments: U.S. Domestic Package, International Package, and Supply Chain & Freight. The U.S. Domestic Package segment offers time-definite delivery of letters, documents, small packages, and palletized freight through air and ground services in the United States.
Shares of Aratana Therapeutics Inc (NASDAQ:PETX), declined -38.97% to $10.68, during its last trading session.
Aratana Therapeutics, offered several product updates. The Company continues to advance its deep pipeline of novel therapeutics, counting four products at pivotal stage (AT-001, AT-002, AT-003 and AT-014), while concluding that post-licensure marketing studies of canine lymphoma products AT-004 and AT-005 will not fully capture the market opportunity. Aratana is pursuing second-generation monoclonal antibodies and other solutions to canine lymphoma.
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio comprises about 18 therapeutic candidates compriseing of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets.
At the end of Friday’s trade, Shares of Sequenom, Inc. (NASDAQ:SQNM), lost -7.21% to $1.93.
Sequenom, a life sciences company committed to enabling healthier lives through the development of innovative products and services, provides its current revenue outlook for the second half of 2015.
The Company is updating its revenue expectations for the second half of the year to a range between $57 million and $61 million, bringing 2015 annual revenue expectations to a range between $127 million and $131 million.
Drivers for the updated expectations comprise raised competition and price compression in the noninvasive prenatal testing (NIPT) market.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
Finally, Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), ended its last trade with -1.75% loss, and closed at $0.899.
Golar LNG Limited advises that the 2015 Annual General Meeting of the Company was held on September 23, 2015 at 9:00 a.m. at Rosewood Tucker`s Point, 60 Tucker`s Point Drive, Hamilton Parish, Bermuda. The audited merged financial statements for the Company for the year ended December 31, 2014 were presented to the Meeting.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. The company operates in two segments, Flight Transportation and Smiles Loyalty Program. As of December 31, 2014, it operated a fleet of 144 aircraft, which comprised 96 aircraft under operating leases, 45 aircraft under finance leases, and 3 aircraft owned by the company.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
